Orgenesis investor relations material

Orgenesis Inc. is engaged in the development, manufacture, and commercialization of cell and gene therapies (CGTs) for diabetes and other serious chronic medical conditions. We are currently focused on developing a stem cell therapy-based treatment for patients with type 1 diabetes that do not produce insulin. Our product, “MAVENcell,” could potentially become the first non-immunosuppressive pancreatic islet cell transplantation therapy and lead to a cure for every individual who has lost their insulin producing ability. Orgenesis Inc. was founded in 2008 and is based in Germantown, Maryland.